Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

BACKGROUND: To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael A., McGuire, Darren K., Pieper, Karen S., Lokhnygina, Yuliya, Strandberg, Timo E., Riefflin, Axel, Delibasi, Tuncay, Peterson, Eric D., White, Harvey D., Scott, Russell, Holman, Rury R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719352/
https://www.ncbi.nlm.nih.gov/pubmed/31481069
http://dx.doi.org/10.1186/s12933-019-0921-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719352/
https://www.ncbi.nlm.nih.gov/pubmed/31481069
http://dx.doi.org/10.1186/s12933-019-0921-2

Ejemplares similares